A compound having the formula: wherein Y-X is -C(R 7)(R 7a)N(R')C -; -C(R 7)(R 7a)OC -; -C(R 7)(R 7a)N(R')C(R 6)(R 6a)-; -C(R 7)(R 7a)S 2 C(R 6)(R 6a)-; -S 2 C(R 6)(R 6a)-; -C(R 7)(R 7a)C(R 6)(R 6a)-; -O-C(R 6)(R 6a)-; -N(R')C(R 6)(R 6a)-; or -C(R 7)(R 7a)OC(R 6)(R 6a)-, wherein each of R 6, R 6a, R 7, and R 7a, is, independently, selected from H, C 1-6 alkyl, C 1-6 fluoroalkyl, benzyl, phenyl and heterocycle, R' is selected from H, C 1-6 alkyl, benzyl, S 2 R", and C R", and R" is selected from C 1-6 alkyl, C 1-6 fluoroalkyl, benzyl, phenyl and heterocycle; when Q is H, P and R 3 are absent; when Q is CH 3, P and R 3 are absent; Q is CH 2, or C; when P is H, R 3 is absent; P is -O-, -N(R 8)(R 8a), or is absent, wherein R 8 and R 8a are selected independently from the group consisting of H, C 1-6 alkyl, C 1-6 fluoroalkyl, benzyl, phenyl and heterocycle; R 1 is absent, C 1-6 alkyl, C 1-6 branched alkyl, C 1-6 alkene, halogen (F, Cl, Br, I), OH, -O-(C 1-6 alkyl), -O-(C 1-6 branched alkyl), -C (R 9), -C O(R 9), -C N(R 9)(R 9a), or -S 2 N(R 9)(R 9a), wherein R 9 and R 9a are selected independently from the group consisting of H, C 1-6 alkyl, C 1-6 fluoroalkyl, benzyl, phenyl and heterocycle; R 2 is absent, C 1-6 alkyl, C 1-6 branched alkyl, C 1-6 alkene, halogen (F, Cl, Br, I), OH, -O-(C 1-6 alkyl), -O-(C 1-6 branched alkyl), -C (R 10), -C O(R 10), or -C N(R 10)(R 10a), wherein R 10 and R 10a are selected independently from the group consisting of H, C 1-6 alkyl, C 1-6 fluoroalkyl, benzyl, phenyl and heterocycle; or R 1 and R 2 are ortho substituents that together form a carbocyclic or heterocyclic ring system; R 3 is H, C 1-6 alkyl, C 1-6 fluoroalkyl, benzyl, phenyl, heterocycle, or is absent; R 5 is H, C 1-6 alkyl, C 1-6 fluoroalkyl, benzyl, phenyl, or heterocycle; or R 3 and R 5 combine to form a heterocyclic ring system; R 4 is H, C 1-6 alkyl, C 1-6 fluoroalkyl, benzyl, phenyl, or heterocycle; and m is 0 or 1; or a pharmaceutically acceptable salt or solvate thereof, for use as a medicament for lowering the cholesterol level in the bloodstream of a subject, for treating atherosclerosis, hypercholesterolemia, hypertriglyceridemia, diabetic complications, dyslipidemia, hyperlipidemia, hypoalphalipoproteinemia, metabolic syndrome, stroke, vascular dementia, chronic kidney disease, coronary heart disease, coronary artery disease, retinopathy, inflammation, thrombosis, peripheral vascular disease or congestive heart failure, for inducing low density lipoprotein receptor (LDLR) expression in a cell or a tissue, or for inducing or stabilizing LDLR mRNA activity in a cell or a tissue. Y-X is -C(R 7)(R 7a)N(R')C -; -C(R 7)(R 7a)OC -; -C(R 7)(R 7a)N(R')C(R 6)(R 6a)-; -C(R 7)(R 7a)S 2 C(R 6)(R 6a)-; -S 2 C(R 6)(R 6a)-; -C(R 7)(R 7a)C(R 6)(R 6a)-; -O-C(R 6)(R 6a)-; -N(R')C(R 6)(R 6a)-; or -C(R 7)(R 7a)OC(R 6)(R 6a)-, wherein each of R 6, R 6a, R 7, and R 7a, is, independently, selected from H, C 1-6 alkyl, C 1-6 fluoroalkyl, benzyl, phenyl and heterocycle, R' is selected from H, C 1-6 alkyl, benzyl, S 2 R", and C R", and R" is selected from C 1-6 alkyl, C 1-6 fluoroalkyl, benzyl, phenyl and heterocycle; when Q is H, P and R 3 are absent; when Q is CH 3, P and R 3 are absent; Q is CH 2, or C; when P is H, R 3 is absent; P is -O-, -N(R 8)(R 8a), or is absent, wherein R 8 and R 8a are selected independently from the group consisting of H, C 1-6 alkyl, C 1-6 fluoroalkyl, benzyl, phenyl and heterocycle; R 1 is absent, C 1-6 alkyl, C 1-6 branched alkyl, C 1-6 alkene, halogen (F, Cl, Br, I), OH, -O-(C 1-6 alkyl), -O-(C 1-6 branched alkyl), -C (R 9), -C O(R 9), -C N(R 9)(R 9a), or -S 2 N(R 9)(R 9a), wherein R 9 and R 9a are selected independently from the group consisting of H, C 1-6 alkyl, C 1-6 fluoroalkyl, benzyl, phenyl and heterocycle; R 2 is absent, C 1-6 alkyl, C 1-6 branched alkyl, C 1-6 alkene, halogen (F, Cl, Br, I), OH, -O-(C 1-6 alkyl), -O-(C 1-6 branched alkyl), -C (R 10), -C O(R 10), or -C N(R 10)(R 10a), wherein R 10 and R 10a are selected independently from the group consisting of H, C 1-6 alkyl, C 1-6 fluoroalkyl, benzyl, phenyl and heterocycle; or R 1 and R 2 are ortho substituents that together form a carbocyclic or heterocyclic ring system; R 3 is H, C 1-6 alkyl, C 1-6 fluoroalkyl, benzyl, phenyl, heterocycle, or is absent; R 5 is H, C 1-6 alkyl, C 1-6 fluoroalkyl, benzyl, phenyl, or heterocycle; or R 3 and R 5 combine to form a heterocyclic ring system; R 4 is H, C 1-6 alkyl, C 1-6 fluoroalkyl, benzyl, phenyl, or heterocycle; and m is 0 or 1; or